AstraZeneca: Leukemia trials
The registry lists 17 Leukemia studies with AstraZeneca as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 11Phase 2 7Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingNCT07509151Phase 3
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingNCT06137118Phase 1/2
- Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01466153Phase 2Results posted
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMTerminatedNCT00648739Phase 1/2Results posted
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedNCT00587457Phase 1Results posted
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell LeukemiaApproved for marketingNCT03501615
- Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) PatientsTerminatedNCT01489722Phase 1
- Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AMLCompletedNCT00502385Phase 1
- Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic MalignanciesTerminatedNCT00460460Phase 1
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1
- Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/LeukemiaTerminatedNCT00105313Phase 1
- Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid LeukemiaCompletedNCT00086099Phase 1/2
- BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaSuspendedNCT00077493Phase 1
- BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell LeukemiaCompletedNCT00074048Phase 2